Acquisition / mergerFiled on BSE ·
Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million
What the filing says
- Board approved up to EUR 45 million additional investment in Mankind Pharma (Netherlands) B.V., increasing total limit to EUR 50 million on October 15, 2026
- Mankind Pharma (Netherlands) to acquire 70% stake in Belgium-based Armed Cell Therapeutics, focused on next-generation CAR-T cancer therapies
- Armed Cell Therapeutics pipeline includes treatments for non-Hodgkin lymphoma and small cell lung cancer, with R&D teams in US and EU
Original filing
Announcement under Regulation 30 (LODR)-Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Mankind Pharma Ltd
Other acquisition / merger filings this fortnight
- Acquisition / mergerAeroflex Enterprises LtdAeroflex Neu Limited approves acquisition of 51.01% stake in Stilonn Valves and Controls Pvt Ltd
- Acquisition / mergerAllcargo Logistics LtdAllcargo Logistics files SEBI exemption order for share acquisition by Shetty Trust
- Acquisition / mergerBaazar Style Retail LtdBaazar Style Retail Ltd appoints director, incorporates subsidiary, issues shares
- Acquisition / mergerCSB Bank LtdCSB Bank clarifies it is not involved in merger talks with IDBI Bank after Fairfax deal news
- Acquisition / mergerAXISCADES Technologies LtdAXISCADES' XIDA to acquire Silicon Valley-based ITSJ business for AI hardware expansion
- Acquisition / mergerMoneyview LtdMoneyview Limited invests ₹250 crore in wholly owned subsidiary Whizdm Finance Pvt Ltd
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.